Nobuhiro Inoue | Neuropharmacology | Best Researcher Award

Dr. Nobuhiro Inoue | Neuropharmacology | Best Researcher Award

Dr. Nobuhiro Inoue | Kumamoto Neurosurgical Hospital | Japan

Dr. Nobuhiro Inoue is a distinguished neurosurgeon affiliated with Kumamoto Neurosurgical Hospital in Japan, recognized for his extensive contributions to the field of neurosurgery and neurological research. His clinical expertise encompasses advanced microsurgical techniques, neurotrauma management, cerebrovascular disorders, and brain tumor surgery. Dr. Inoue has published numerous scientific papers in reputable international journals, reflecting his commitment to advancing medical knowledge and improving neurosurgical outcomes. His research often focuses on the pathophysiology of brain and spinal diseases, the development of minimally invasive surgical methods, and innovative neuroimaging applications in clinical practice. As an active contributor to academic and clinical advancements, Dr. Inoue collaborates with interdisciplinary teams to integrate cutting-edge technology and evidence-based approaches in patient care. His scientific works have been widely cited, underscoring their influence on neurosurgical research and education. Through his dedication to both surgery and scientific inquiry, Dr. Nobuhiro Inoue continues to play a vital role in enhancing the understanding and treatment of complex neurological conditions in Japan and beyond.

Profile: Orcid

Featured Publications

Inoue, N., & Goto, S. (2025). Clinical evidence of senile choreo-athetosis following valproate withdrawal: A case report. Neurology and Clinical Neuroscience.

Inoue, N. (2020). Post-stroke dizziness of visual vestibular cortices origin. Journal of Neuroscience and Neurological Disorders.

Inoue, N. (2017). Severe ischemic stroke due to progression of cervical carotid artery dissection. Neurological Research and Therapy, 17(22).

Inoue, N. (2015). Cerebral blood flow in the visual and parieto-insular vestibular cortices in patients after cerebral ischemia with or without dizziness. International Journal of Neurological Disorders & Interventions, 101.

Inoue, N. (2014). Effect of ibudilast on the reciprocal inhibitory visual-vestibular interaction closely related to dizziness after cerebral ischemia. Journal of Stroke and Cerebrovascular Diseases, 23, 51–55.

Inoue, N. (2011). Highly purified eicosapentaenoic acid improves cerebral vasomotor-reactivity in patients with chronic cerebral ischemia. Therapeutic Research, 32, 1325–1332.

Inoue, N. (2010). Long-term suppression of Meige syndrome after pallidal stimulation: A 10-year follow-up study. Movement Disorders, 25(11), 1753–1763.

Inoue, N. (2009). Relationship between dizziness and cerebral blood flow in patients with chronic cerebral ischemia. In A. Lindqvist & G. Nyman (Eds.), Dizziness: Vertigo, disequilibrium and lightheadedness. Nova Science Publishers. ISBN 978-1-60741-847-4

Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Prof. Dr. Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Prof. Dr. Hongrui Meng,  Institute of Neuroscience, Soochow University, China.

Dr. Hongrui Meng is a highly accomplished neuroscientist whose academic path began with a Ph.D. in Behavioural Neuroscience from Hamamatsu University School of Medicine in Japan. He later conducted postdoctoral research in molecular neurobiology and human genetics at Juntendo University, Tokyo. Currently a professor at the Institute of Neuroscience, Soochow University, Dr. Meng leads a research team dedicated to uncovering the molecular and mitochondrial mechanisms underlying Parkinson’s disease and ALS. His work spans high-impact research projects funded by JSPS, NSFC, and other prestigious bodies. In addition to numerous scientific publications, he has contributed to diagnostic innovation through patented miRNA detection methods. His influence extends beyond academia through translational applications such as wearable technologies for Parkinson’s symptom monitoring.

Profile

Orcid

🎓 Early Academic Pursuits

Dr. Hongrui Meng began his distinguished academic journey in the field of neuroscience by earning his Ph.D. in Behavioural Neuroscience from the prestigious Hamamatsu University School of Medicine in Japan. His early education and training laid a strong foundation in experimental neuroscience, with a focus on the behavioral manifestations of neurodegenerative conditions. These formative years not only sharpened his scientific curiosity but also equipped him with the cross-disciplinary expertise to address complex neurological questions.

🧠 Professional Endeavors

Following his doctoral studies, Dr. Meng advanced his specialization through postdoctoral training in molecular neurobiology and human genetics at Juntendo University in Tokyo. There, he immersed himself in high-level research focusing on the genetic underpinnings of neurological disorders. His competence and dedication soon earned him a faculty appointment as an Assistant Professor in the Department of Research for Neurodegenerative Diseases and Dementia. His professional arc reached a significant milestone in 2020 when he was promoted to Full Professor and moved to the Institute of Neuroscience at Soochow University, where he now leads the Laboratory of Molecular Neurology.

🧬 Contributions and Research Focus

Dr. Meng’s scientific contributions center on the molecular mechanisms of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). His research bridges mitochondrial dysfunction, alpha-synuclein aggregation, and neurodegeneration. He has completed pivotal studies supported by the Japan Society for the Promotion of Science and the Takeda Pharmaceutical Foundation, delving into the role of CHCHD2 gene mutations and mitochondrial pathways. His ongoing projects funded by the National Natural Science Foundation of China (NSFC) explore mitochondrial unfolded protein responses (mtUPR), while another innovative project in Suzhou focuses on wearable technology for monitoring Parkinson’s disease symptoms—demonstrating his commitment to translational and patient-centered neuroscience.

🔬 Innovation and Scientific Output

A notable innovator, Dr. Meng has made strides in molecular diagnostic technologies. His work has led to the development of high-throughput RT-qPCR-based methods for detecting primary and precursor miRNAs, contributing to enhanced genetic analysis of neurodegenerative disorders. He holds a patent granted in South Africa and another under process in China, underscoring his role at the intersection of research and technology. Furthermore, his publications in highly regarded journals like Current Issues in Molecular Biology and Cell Communication and Signaling reflect a consistent record of impactful findings that inform both fundamental neuroscience and clinical approaches.

🏅 Accolades and Recognition

Dr. Meng’s ascent in the academic community has been marked by numerous grants, including multiple from the JSPS and NSFC, attesting to the trust placed in his research vision by top funding bodies. While a formal list of awards may be under-documented, his rapid progression from postdoctoral fellow to professor and research team leader in less than a decade speaks volumes about his recognition among peers and institutional leadership. His leadership in multi-disciplinary and international collaborations is an implicit accolade of his scientific reliability and visionary perspective.

🌍 Impact and Influence

Through his groundbreaking work on mitochondrial mechanisms and neurodegeneration, Dr. Meng is helping to reshape current understanding of Parkinson’s disease pathophysiology. His investigations into alpha-synucleinopathy and microglial disruption have provided fresh insights into cellular degeneration and neuroimmune interactions. Beyond academia, his involvement in developing wearable diagnostic tools highlights his drive to impact patient lives directly. As a consultant on neuroprotective treatments such as PD-018/19, he bridges the academic and pharmaceutical worlds to accelerate therapeutic discovery.

🔮 Legacy and Future Contributions

Looking forward, Dr. Meng is poised to be a leading figure in neurogenetic diagnostics and therapeutic innovation. His laboratory at Soochow University serves as an incubator for future discoveries in neurodegenerative disease mechanisms, and his continued work in mitochondrial research promises to inform emerging therapies. With a growing publication record, international patents, and a robust research pipeline, Dr. Meng’s legacy will be one of bridging basic neuroscience with clinical application—paving the way for novel interventions and a better understanding of brain disorders in the molecular era.

Publication

 

  • Title: Dicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency
    Authors: Xiang Long, Yijie Wang, Hongrui Meng
    Year: 2025

 

  • Title: Transcriptomic analysis of lipid metabolism genes in Alzheimer’s disease: highlighting pathological outcomes and compartmentalized immune status
    Authors: Sun Y., Zhang Y., Jiang M., Long X., Miao Y., Du H., Zhang T., Meng H., Ma X.
    Year: 2024

 

  • Title: CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis
    Authors: Aya Ikeda, Hongrui Meng, Daisuke Taniguchi, Muneyo Mio, Manabu Funayama, Kenya Nishioka, Mari Yoshida, Yuanzhe Li, Hiroyo Yoshino, Tsuyoshi Inoshita et al.
    Year: 2024

 

  • Title: TDP-43 mutations-induced defects in miRNA biogenesis and cytotoxicity by differentially obstructing Dicer activity in Drosophila and in vitro
    Authors: Xiang Long, Mengni Jiang, Yongzhen Miao, Huanhuan Du, Ting Zhang, Zhuoya Ma, Jiao Li, Chunfeng Liu, Hongrui Meng
    Year: 2024

 

  • Title: A Simple Technique to Assay Locomotor Activity in Drosophila
    Authors: Long X., Du H., Jiang M., Meng H.
    Year: 2023

 

  • Title: Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression
    Authors: Meng H.-R., Suenaga T., Edamura M., Nakahara D., Murakami G., Fukuda A., Ishida Y.
    Year: 2021

 

  • Title: Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson’s disease
    Authors: Imai Y., Hattori N., Inoshita T., Shiba-Fukushima K., Meng H., Hara K.Y., Sawamura N.
    Year: 2019

 

  • Title: Mutations in CHCHD2 cause α-synuclein aggregation
    Authors: Ikeda A., Nishioka K., Takanashi M., Li Y., Mori A., Okuzumi A., Izawa N., Ishikawa K.-I., Funayama M., Imai Y. et al.
    Year: 2019

 

  • Title: Parkinson’s disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling
    Authors: Mori A., Hatano T., Koinuma T., Kubo S.-I., Spratt S., Yamashita C., Okuzumi A., Imai Y., Hattori N., Inoshita T. et al.
    Year: 2019

 

  • Title: Twin CHCH proteins, CHCHD2, and CHCHD10: Key molecules of Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia
    Authors: Imai Y., Hattori N., Meng H., Shiba-Fukushima K.
    Year: 2019

 

🧾 Conclusion

Dr. Hongrui Meng’s career reflects a dynamic blend of academic excellence, molecular research innovation, and translational neuroscience. His scientific endeavors have not only enriched the understanding of neurodegenerative diseases but have also paved the way for novel diagnostic and therapeutic strategies. With a growing portfolio of impactful research, patents, and leadership in neurobiology, Dr. Meng stands out as a driving force in the global fight against neurological disorders. His work promises continued contributions to neuroscience with lasting influence on both scientific knowledge and patient care.

 

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.